NovoCure Ltd. is a healthcare company based in the United Kingdom. Specializing in the development and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for treating solid tumor cancers. With a medium risk ESG score of 27.4, NovoCure Ltd. has a pipeline of products like Trident, Lunar-2, Panova-3, Metis for the treatment of Glioblastoma, Non-smell cell lung cancer, and Pancreatic cancer. Majority of their revenue comes from the United States, with additional income from markets like Germany and Japan.